News
-
-
-
COMMUNIQUÉ DE PRESSE
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
APONTIS PHARMA reports profitable revenue growth with Single Pill combinations in the first half of 2024. Forecast for full year 2024 confirmed. Earnings and sales improvements noted -
-
-
COMMUNIQUÉ DE PRESSE
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board to enhance strategic development, internationalization, and ESG strategy. CFO brings strong financial expertise -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on APONTIS PHARMA AG with a Buy rating and EUR 17.00 price target. Apontis focuses on cardiovascular and respiratory drugs in Germany, led by CEO Wohlschlegel to drive efficiency and growth -
